Panacea Biotec completes Phase I/II study of DengiAll vaccine

By: |
September 24, 2020 5:24 PM

DengiAll is a single-dose live-attenuated tetravalent vaccine. ''Lt induced robust, balanced neutralising antibody responses against all the four dengue virus serotypes", it said.

DengiAll's Phase I/II study results are even more important in the context of the COVID-19 pandemic.DengiAll's Phase I/II study results are even more important in the context of the COVID-19 pandemic.

Drug firm Panacea Biotec on Thursday said it has successfully completed Phase I/II clinical study to evaluate the safety and immunogenicity of its DengiAll vaccine.

According to the World Health Organization, dengue represents one of the 10 biggest global health threats and it is critical to have access to a safe and effective vaccine candidate that can reduce the devastating impact of dengue fever in endemic regions, Panacea Biotec said in a BSE filing.

DengiAll is a single-dose live-attenuated tetravalent vaccine. ”Lt induced robust, balanced neutralising antibody responses against all the four dengue virus serotypes”, it said.

“DengiAll’s Phase I/II study results are even more important in the context of the COVID-19 pandemic. Co-infection of dengue and COVID-19 in a dengue-endemic India may complicate approach to treatment and strain health care infrastructure,” Panacea Biotec MD Rajesh Jain said.

The company has already approached the Drugs Controller General of India (DCGI) to seek accelerated review of its data to bring DengiAll to market quickly and reduce burden on the country’s healthcare infrastructure, he added.

Shares of Panacea Biotec were trading at Rs 196.80 per scrip on BSE, up 4.99 per cent from its previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Sanofi, Glaxo to Supply 200 million Covid vaccine doses to Covax
2COVID-19 patients could suffer cognitive deficits equal to brain ageing by 10 years, says study
3China reports 42 new confirmed COVID-19 cases